Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) Interest Expenses (2020 - 2025)

Unicycive Therapeutics filings provide 3 years of Interest Expenses readings, the most recent being $20000.0 for Q4 2024.

  • On a quarterly basis, Interest Expenses rose 5.26% to $20000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $71000.0, a 12.35% decrease, with the full-year FY2025 number at $71000.0, changed 0.0% from a year prior.
  • Interest Expenses hit $20000.0 in Q4 2024 for Unicycive Therapeutics, up from $15000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $32000.0 in Q2 2023 to a low of $3000.0 in Q3 2022.
  • Median Interest Expenses over the past 3 years was $17000.0 (2023), compared with a mean of $15800.0.
  • Biggest five-year swings in Interest Expenses: soared 533.33% in 2023 and later crashed 50.0% in 2024.
  • Unicycive Therapeutics' Interest Expenses stood at $3000.0 in 2022, then soared by 533.33% to $19000.0 in 2023, then rose by 5.26% to $20000.0 in 2024.
  • The last three reported values for Interest Expenses were $20000.0 (Q4 2024), $15000.0 (Q3 2024), and $16000.0 (Q2 2024) per Business Quant data.